PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
Mary J. Fidler, Philip Bonomi(Rush University Medical Center), Susan Jewell(Netherlands Institute for Radio Astronomy), Marta Batus(Rush University Medical Center), Lela Buckingham(Rush University Medical Center), Larry E. Morrison(Abbott Fund), J Thompson Coon(Rush University Medical Center), Sanjib Basu(Rush University Medical Center), Kristine Jacobson(Abbott (United States)), Kelli Walters(Rush University Medical Center)
Cited by 20
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
|Journal of Clinical Oncology|2004|1.1k
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
|The American Journal of Surgical Pathology|2009|470
A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms
|The American Journal of Surgical Pathology|2012|227